Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
NCT Number: NCT06609174
The purpose of this study is to assess the feasibility and impact of screening FDR of DCM probands using a mobile ECG with the ability to transmit the ECG for cloud-based AI analysis to detect reduced left ventricular ejection fraction (LVEF). This protocol will examine the impact of incorporating the screening AI enhanced ECG into standard of care recommendations.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Rochester, Minnesota, 55905, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
(Proband)
Inclusion criteria
(FDR)
Exclusion criteria
(Proband)
Exclusion criteria
(FDR)
The Kardia 6-lead device is an ambulatory, wireless device that connects to a smartphone. The KardiaRx App processes the signal acquired from the Kardia device into a real-time ECG. ECG will be interpreted by an AI algorithm
Time frame: Baseline
Measured by the number of complete transmissions from the Kardia 6-lead device to the AI-ECG algorithm.
Time frame: Baseline
The following screening procedures will be considered a valid cardiac screening attempt:
Time frame: Baseline
Left Ventricular Ejection Fraction will be determined by AI-ECG
Mayo Clinic
Other
Artificial Intelligence Electrocardiogram Enabled Mobile Device in Screening Families for Dilated Cardiomyopathy (The AI-SCREENDCM Decentralized Clinical Trial Pilot Study)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03057561
Arterial Occlusive Diseases, Arteriosclerosis
View Trial DetailsNCT01143519
Cancer, Cardiomyopathies
Research Triangle Park, North Carolina, United States
View Trial DetailsNCT07272330
Cardiomyopathies, Cardiomyopathy
Beijing, Beijing Municipality, China
View Trial DetailsNCT01648634
Cardiomyopathies, Cardiomyopathy
Paris, France
View Trial Details